Extensive studies in humans and animal models indicate that acquired immunity to malaria develops. Yet, the goal of reducing morbidity and mortality due to malaria through active immunization has not been achieved. Our efforts to identify plasmodial antigens that trigger protective responses are focused on an in vivo system of immunization-induced protection. Using this Plasmodium yoelii model, we identified a novel merozoite surface antigen and a unique family of antigens secreted from infected erythrocytes. We provided evidence of their vaccine potential in the P. yoelii model and of their conservation in Plasmodium falciparum. The objective of this application is to evaluate the efficacy of immunization with conserved domains of these protective antigens. The hypothesis is that the tryptophan-rich domain (WRD) of secreted blood-stage malarial antigens and the epidermal growth factor (EGF)-like domains of merozoite surface protein-6 (MSP-6) are targets of protective immune responses. The efficacy of immunization with conserved domains of pyWRD and pyMSP-6 antigens will be measured as protection against blood-stage P. yoelii malaria. Vaccine formulations and delivery systems will be manipulated to optimize protection induced by immunization with recombinant P. yoelii WRD and MSP-6 antigens administered in combination with merozoite surface protein -1. T cell and B cell responses that correlate with protection induced by immunization with combinations of P. yoelii antigens expressing WRD and EGF-like domains will be defined. As the immune responses to these domains in the P. yoelii model are characterized, the findings will be directly applied to studies of P. falciparum. The ability of rabbit antisera raised against recombinant pfWRD and pfMSP-6 to inhibit the in vitro growth of P. falciparum will be evaluated. Using an integrated approach, novel blood-stage vaccine targets that can be effectively formulated in combination to increase the efficacy of immunization will be characterized. The results will provide a logical basis for planning and evaluating human trials of a multivalent, blood-stage vaccine that includes the WRD and EGF-like domains of these P. falciparum antigens.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI035661-09
Application #
6698818
Study Section
Special Emphasis Panel (ZRG1-VACC (01))
Program Officer
Wali, Tonu M
Project Start
1995-09-30
Project End
2006-01-31
Budget Start
2004-02-01
Budget End
2005-01-31
Support Year
9
Fiscal Year
2004
Total Cost
$302,000
Indirect Cost
Name
Drexel University
Department
Microbiology/Immun/Virology
Type
Schools of Medicine
DUNS #
002604817
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Burns Jr, James M; Miura, Kazutoyo; Sullivan, JoAnn et al. (2016) Immunogenicity of a chimeric Plasmodium falciparum merozoite surface protein vaccine in Aotus monkeys. Malar J 15:159
Alaro, James R; Partridge, Andrea; Miura, Kazutoyo et al. (2013) A chimeric Plasmodium falciparum merozoite surface protein vaccine induces high titers of parasite growth inhibitory antibodies. Infect Immun 81:3843-54
Alaro, James R; Angov, Evelina; Lopez, Ana M et al. (2012) Evaluation of the immunogenicity and vaccine potential of recombinant Plasmodium falciparum merozoite surface protein 8. Infect Immun 80:2473-84
Thorat, Swati; Daly, Thomas M; Bergman, Lawrence W et al. (2010) Elevated levels of the Plasmodium yoelii homologue of macrophage migration inhibitory factor attenuate blood-stage malaria. Infect Immun 78:5151-62
Alaro, James R; Lynch, Michele M; Burns Jr, James M (2010) Protective immune responses elicited by immunization with a chimeric blood-stage malaria vaccine persist but are not boosted by Plasmodium yoelii challenge infection. Vaccine 28:6876-84
Petritus, Patricia M; Burns Jr, James M (2008) Suppression of lethal Plasmodium yoelii malaria following protective immunization requires antibody-, IL-4-, and IFN-gamma-dependent responses induced by vaccination and/or challenge infection. J Immunol 180:444-53
Shi, Qifang; Lynch, Michelle M; Romero, Margarita et al. (2007) Enhanced protection against malaria by a chimeric merozoite surface protein vaccine. Infect Immun 75:1349-58
Shi, Qifang; Cernetich-Ott, Amy; Lynch, Michelle M et al. (2006) Expression, localization, and erythrocyte binding activity of Plasmodium yoelii merozoite surface protein-8. Mol Biochem Parasitol 149:231-41
Shi, Qifang; Cernetich, Amy; Daly, Thomas M et al. (2005) Alteration in host cell tropism limits the efficacy of immunization with a surface protein of malaria merozoites. Infect Immun 73:6363-71